Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art
Antipsychotics are the main pharmaceutical agents in treatment of schizophrenia and other mental disorders. According to literature data up to 60% of patients with schizophrenia have antipsychotic-induced metabolic disturbances. The main objective of pharmacogenetic studies is search for predictors...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation
2018-07-01
|
| Series: | Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева |
| Subjects: | |
| Online Access: | https://www.bekhterevreview.com/jour/article/view/33 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388909043122176 |
|---|---|
| author | R. F. Nasyrova N. A. Sivakova D. V. Ivashchenko D. N. Sosin E. E. Ershov K. A. Sosina L. Sh. Akhmetova O. V. Volikova T. Z. Beybalayeva N. G. Neznanov |
| author_facet | R. F. Nasyrova N. A. Sivakova D. V. Ivashchenko D. N. Sosin E. E. Ershov K. A. Sosina L. Sh. Akhmetova O. V. Volikova T. Z. Beybalayeva N. G. Neznanov |
| author_sort | R. F. Nasyrova |
| collection | DOAJ |
| description | Antipsychotics are the main pharmaceutical agents in treatment of schizophrenia and other mental disorders. According to literature data up to 60% of patients with schizophrenia have antipsychotic-induced metabolic disturbances. The main objective of pharmacogenetic studies is search for predictors of the response to therapy and definition of likelihood of development of undesirable phenomena. The main findings in the field of pharmacogenetics of metabolic disturbances were analysed. Recently, significant progress in the field of pharmacogenetic research was made which confirmed results of the previous studies and revealed new candidate genes. Ambiguous results in pharmacogenetic studies may be a reflection of complexity of pathogenesis of antipsychotic-induced weight gain, an influence of a set of epigenetic factors on mechanisms of its development. All this complicates design of the studies directed at identification of the candidate genes participating in realization of metabolic disturbances during intake of neuroleptics. Improvement of pharmacogenetic studies will provide the best understanding of how these genes are associated with antipsychotic-induced metabolic disturbances. Inclusion of pharmacogenetic approach in clinical guidelines is necessary, but now it is complicated that is associated mainly with the insufficient level of validity of the genetic markers studied and their ethnic heterogeneity. Use of pharmacogenetic testing improves rational therapy and contributes to the most efficient and safe therapy. |
| format | Article |
| id | doaj-art-0ad98d933d4146cebafa2a3d7f6497e9 |
| institution | Kabale University |
| issn | 2313-7053 2713-055X |
| language | Russian |
| publishDate | 2018-07-01 |
| publisher | Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation |
| record_format | Article |
| series | Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева |
| spelling | doaj-art-0ad98d933d4146cebafa2a3d7f6497e92025-08-20T03:42:07ZrusFederal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian FederationОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева2313-70532713-055X2018-07-0103678033Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-artR. F. Nasyrova0N. A. Sivakova1D. V. Ivashchenko2D. N. Sosin3E. E. Ershov4K. A. Sosina5L. Sh. Akhmetova6O. V. Volikova7T. Z. Beybalayeva8N. G. Neznanov9Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваСанкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваСанкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваСанкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваСПб ГБУЗ «Психиатрическая больница №1 им. П.П. Кащенко»Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваКазанский государственный медицинский университетАлтайский государственный медицинский университетКазанский государственный медицинский университетСанкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. БехтереваAntipsychotics are the main pharmaceutical agents in treatment of schizophrenia and other mental disorders. According to literature data up to 60% of patients with schizophrenia have antipsychotic-induced metabolic disturbances. The main objective of pharmacogenetic studies is search for predictors of the response to therapy and definition of likelihood of development of undesirable phenomena. The main findings in the field of pharmacogenetics of metabolic disturbances were analysed. Recently, significant progress in the field of pharmacogenetic research was made which confirmed results of the previous studies and revealed new candidate genes. Ambiguous results in pharmacogenetic studies may be a reflection of complexity of pathogenesis of antipsychotic-induced weight gain, an influence of a set of epigenetic factors on mechanisms of its development. All this complicates design of the studies directed at identification of the candidate genes participating in realization of metabolic disturbances during intake of neuroleptics. Improvement of pharmacogenetic studies will provide the best understanding of how these genes are associated with antipsychotic-induced metabolic disturbances. Inclusion of pharmacogenetic approach in clinical guidelines is necessary, but now it is complicated that is associated mainly with the insufficient level of validity of the genetic markers studied and their ethnic heterogeneity. Use of pharmacogenetic testing improves rational therapy and contributes to the most efficient and safe therapy.https://www.bekhterevreview.com/jour/article/view/33антипсихотикиперсонализированная медицинашизофренияметаболические нарушенияфармакогенетикаantipsychoticspersonalized medicineschizophreniametabolic disturbancespharmacogenetics |
| spellingShingle | R. F. Nasyrova N. A. Sivakova D. V. Ivashchenko D. N. Sosin E. E. Ershov K. A. Sosina L. Sh. Akhmetova O. V. Volikova T. Z. Beybalayeva N. G. Neznanov Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева антипсихотики персонализированная медицина шизофрения метаболические нарушения фармакогенетика antipsychotics personalized medicine schizophrenia metabolic disturbances pharmacogenetics |
| title | Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art |
| title_full | Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art |
| title_fullStr | Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art |
| title_full_unstemmed | Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art |
| title_short | Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art |
| title_sort | pharmacogenetics of antipsychotic induced metabolic disturbances state of the art |
| topic | антипсихотики персонализированная медицина шизофрения метаболические нарушения фармакогенетика antipsychotics personalized medicine schizophrenia metabolic disturbances pharmacogenetics |
| url | https://www.bekhterevreview.com/jour/article/view/33 |
| work_keys_str_mv | AT rfnasyrova pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT nasivakova pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT dvivashchenko pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT dnsosin pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT eeershov pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT kasosina pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT lshakhmetova pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT ovvolikova pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT tzbeybalayeva pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart AT ngneznanov pharmacogeneticsofantipsychoticinducedmetabolicdisturbancesstateoftheart |